29 completed. 8 Phase 3, 6 Phase 1, 5 Phase 2, 4 Phase 4, 1 Not applicable.
By phase and status
Follow Rabeprazole Sodium: new trials by email Literature Review of Rabeprazole Sodium trials Research Report on Rabeprazole Sodium
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
Efficacy and Safety After Multiple Doses of TNP-2198 Capsules, Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules in Helicobacter Pylori Infected-positive Participants TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection Phase 2 Completed 80 2022-06-26 2023-12-12 A Study in Healthy Men to Compare Two Different Oral Formulations of BI 1810631 and to Test How Food or Rabeprazole Influence the Amount of BI 1810631 in the Blood BI 1810631 - trial formulation 1 (TF1), BI 1810631 - new formulation (NF), Rabeprazole sodium - Healthy Phase 1 Completed 13 2022-06-23 2025-11-04 A Study to Evaluate Preliminary Helicobacter Pylori Eradication After Multiple Doses of TNP-2198 Capsules Combined With Rabeprazole Sodium Enteric-coated Tablets, or Rabeprazole Sodium Enteric-coated Tablets and Amoxicillin Capsules TNP-2198, Rabeprazole Sodium, Amoxicillin - Helicobacter Pylori Infection Phase 1 / Phase 2 Completed 40 2021-09-27 2023-11-22 A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer Pariet - Stomach Ulcer, Duodenal Ulcer Completed 676 2020-07-23 2022-11-22 A Phase 2 Randomised Controlled Trial to Evaluate Efficacy and Safety of Anaprazole in Patients With Duodenal Ulcers. Anaprazole Sodium, Rabeprazole sodium - Duodenal Ulcer，DU Phase 2 Completed 150 2018-10-09 2020-08-07 Effect of Proton Pump Inhibitors on Palpitations Rabeprazole sodium, Pacebo - Signs and Symptoms Not applicable Completed 30 2016-10-01 2018-03-13 To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis Z-215 10mg, Z-215 20mg, Z-215 Placebo - Esophagitis, Reflux Phase 2 Completed 503 2015-05-01 2017-07-02 Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438) Vonoprazan, Esomeprazole, Rabeprazole sodium - Healthy Volunteers Phase 3 Completed 20 2014-01-01 2016-10-17 The Study to Evaluate Efficacy and Safety of Newrabell® Tab.(Rabeprazole Sodium) 10mg b.i.d in Refractory GERD Newrabell® Tablet 10mg - Reflux Esophagitis Phase 4 Completed 39 2013-04-01 2015-09-24 Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori Rabeprazole Sodium - Gastric Low-grade MALT Lymphoma With Helicobacter Pylori Positive Completed 108 2011-01-13 2017-02-27 Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis rabeprazole sodium - Refractory Reflux Esophagitis Completed 2157 2011-01-01 2023-07-24 A Pharmacokinetics, Pharmacodynamics and Safety Study of Rabeprazole in New Born Infants With Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium - Gastroesophageal Reflux Phase 1 Completed 69 2009-07-01 2013-04-29 Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD) rabeprazole sodium, Placebo - Symptomatic Gastroesophageal Reflux Disease (sGERD) Phase 3 Completed 305 2009-01-01 2016-02-02 A Pharmacokinetic and Relative Bioavailability Study With Rabeprazole Sodium in Healthy Adult Volunteers rabeprazole sodium - Gastroesophageal Reflux Phase 1 Completed 36 2008-08-01 2014-05-28 Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea Rabeprazole Sodium - Gastroesophageal Reflux Completed 1197 2008-06-01 2014-04-28 A Pharmacokinetic and Safety Study of Single and Multiple Doses of Rabreprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Years Old, Inclusive Rabeprazole sodium - GERD Phase 1 Completed 31 2008-03-01 2011-01-10 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD) Phase 3 Completed 1061 2008-02-01 2015-12-21 Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD) Phase 3 Completed 1069 2008-02-01 2015-12-21 Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD) Rabeprazole sodium, Esomeprazole - Gastroesophageal Reflux Disease (GERD) Phase 3 Completed 1397 2008-02-01 2016-05-04 Study of Changes in Reflux Symptoms and Reflux Finding Score According to Rabeprazole Treatment Period Rabeprazole Sodium - Gastroesophageal Reflux, Pharyngeal Diseases Completed 1142 2007-09-01 2014-04-28
Showing 20 of 29. Sign in to see all of them.
Conditions studied Gastroesophageal Reflux (13) · Esophagitis, Peptic (3) · Heartburn (3) · Stomach Ulcer (2) · Bacterial Infections (1) · Duodenal Ulcer (1) · Helicobacter Infections (1) · Pharyngeal Diseases (1) · Signs and Symptoms (1) · Stomach Neoplasms (1)
Sponsors Eisai Inc. (9) · Eisai Co., Ltd. (3) · Janssen Cilag Pharmaceutica S.A.C.I., Greece (2) · Janssen Korea, Ltd., Korea (2) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (2) · TenNor Therapeutics (Suzhou) Limited (2) · Boehringer Ingelheim (1) · Chong Kun Dang Pharmaceutical (1) · Eisai Korea Inc. (1) · Janssen Research & Development, LLC (1) · Janssen-Ortho Inc., Canada (1) · Jordan Collaborating Cardiology Group (1) · Sihuan Pharmaceutical Holdings Group Ltd. (1) · Takeda (1) · Zeria Pharmaceutical (1)
Countries United States (10) · Japan (6) · Germany (4) · China (3) · Argentina (2) · Australia (2) · Bulgaria (2) · Canada (2) · Chile (2) · Croatia (2) · Estonia (2) · France (2) · Hungary (2) · India (2) · Latvia (2)
Top investigators Yufang Lu (4) · Yufang Lu, MD, PhD (2) · Guillermo Rossiter, MD (1) · Jongsun Rew, Ph.D (1) · Katsuya Sugizaki (1) · Marco Cyrille, MD (1) · Munir Zaqqa, MD (1) · Nobuyuki Sugisaki (1)
Results publications PMID 21114792 , PMID 38359854 , PMID 17116123 , PMID 27129014 , PMID 28502925 , PMID 34336894